Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom
Deutsche Bank analyst James Shin says there are several reasons why Lilly should trade at a premium to Novo Nordisk.
Source: cnbc.com
Fast, Ad-Free News Updates
Stay updated with breaking news from Does Eli Lilly. Real-time updates on events, politics, business and more.